Skip to main content

Table 1 Baseline characteristics

From: Web-based personalised information and support for patients with a neuroendocrine tumour: randomised controlled trial

 

All patients

n = 91

Control group

n = 45

Intervention group

n = 46

Newly diagnosed patients n (%)

25 (27)

13 (29)

12 (26)

Sex (female) n (%)

42 (46)

23 (51)

19 (41)

Age mean in years (sd)

62 (8)

63 (7)

62 (10)

Location of primary tumor: n (%)

 Pancreas

21 (23)

9 (20)

12 (26)

 Intestine

53 (58)

26 (58)

27 (59)

 Stomach/duodenum

3 (3)

2 (4)

1 (2)

 Colorectal

2 (3)

2 (4)

1 (2)

 Bronchopulmonal

1 (1)

1 (2)

0 (0)

 Appendix

1 (1)

1 (2)

0 (0)

 Unknown/other

9 (10)

4 (9)

5 (11)

Duration of disease in months: mean (SD)

41 (56)

33 (38)

50 (66)

Disease grade: n (%)

 1

57 (63)

27 (60)

30 (65)

 2

21 (23)

12 (27)

9 (20)

 Unknown

13 (14)

6 (13)

7 (15)

Marital state (Married) n (%)

75 (82)

34 (76)

41 (89)

Education (Polytechnic or university) n (%)

33 (37)

16 (36)

17 (38)

Internet use n (%)

 Daily

86 (96)

40 (91)

46 (100)

 For information about the disease

78 (87)

37 (82)

41 (89)

Treatment during study: n (%)

 Surgery

7 (8)

2 (4)

5 (11)

 PRRT

2 (2)

1 (2)

1 (2)

 SSA

64 (70)

32 (71)

32 (70)

 Systemic treatment other than SSA

17 (19)

9 (20)

8 (17)

Treatment before study: n (%)

 Surgery

52 (57)

26 (58)

26 (57)

 PRRT

2 (2)

0 (0)

2 (4)

 Radiotherapy

3 (3)

0 (0)

3 (6)

 SSA

65 (71)

32 (71)

33 (72)

 Systemic treatment other than SSA

23 (25)

12 (26)

11 (24)

 Other (RFA)

1 (1)

0 (0)

1 (2)

  1. n = number, PRRT = peptide receptor radionucleide therapy, RFA = radiofrequency ablation, SSA = somatostatin analogue